Human parainfluenza viruses medical therapy

Human parainfluenza viruses Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Human parainfluenza viruses from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Human parainfluenza viruses medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Human parainfluenza viruses medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Human parainfluenza viruses medical therapy
CDC on Human parainfluenza viruses medical therapy
Human parainfluenza viruses medical therapy in the news
Blogs on Human parainfluenza viruses medical therapy
Directions to Hospitals Treating Human parainfluenza viruses
Risk calculators and risk factors for Human parainfluenza viruses medical therapy

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Antimicrobial regimen

• Parainfluenza virus

• 1. Adults

• Preferred regimen: Ribavirin PO/IV 10 mg/kg q8h

• Day 1: Start with 600 mg loading dose THEN 200 mg q8h
• Day 2: 400 mg q8h
• Day 3: Increase the dose to a maximum of 10 mg/kg q8h

• 1.1 In case of adverse events

• Preferred regimen: Decrease dose or discontinue Ribavirin

• 1.2 Creatinine clearance

• 30–50 mL/min: Ribavirin PO/IV maximal 200 mg q8h
• 10–30 mL/min: No recommendation can be given